The latest report on Rheumatology Therapeutics Market by Infinium Global Research gives complete
coverage of the Rheumatology Therapeutics Market by drug class (disease modifying anti-rheumatic,
nonsteroidal anti-inflammatory, corticosteroids, uric acid drugs), disease indication (rheumatoid arthritis,
osteoarthritis, gout, psoriatic arthritis, ankylosing spondylitis), distribution channel (hospital, retail, online
pharmacy) in terms of key trends, market size, forecast and CAGR growth over the period of 2018 to 2024. In
addition, the study covers deep dive into key product and applications trends in the regional markets of
Rheumatology Therapeutics such as North America, Europe, Asia-Pacific and Latin America over the short run
and long run.
The report on global rheumatology therapeutics market is an in depth analysis of the segments and sub-
segments in the rheumatology therapeutics market. The report provides analysis for the global as well as
regional markets over the period of 2016 to 2024. According to report the global rheumatology therapeutics
market is expected to grow at a CAGR of 2.52% over the forecast period of 2018 - 2024.
Market Insight
Ardea Biosciences received approval from FDA for Duzallo (lesinurad and allopurinol) which help to treatment
of hyperuricemia associated with gout. According to FDA, Duzallo combination of two medications with
complementary mechanisms of action with contains lesinurad, a uric acid reabsorption inhibitor, and
allopurinol, a xanthine oxidase inhibitor. Duzallo lowers serum uric acid levels by increasing excretion and
inhibiting production of uric acid. Duzallo is specifically indicated for the treatment of hyperuricemia
associated with gout in patients who have not achieved target serum uric acid levels with a medically
appropriate daily dose of allopurinol alone. Recently, Sanofi and Regeneron announce FDA approval of
Kevzara (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients.
Kevzara is an interlukin-6 receptor antibody, which is used for treating adult patients with moderate to severe
stages of active rheumatoid arthritis (RA) who have shown indecisive response or intolerance to one or more
Infinium Global Research